TriSalus Life Sciences, Inc. announced an underwriting agreement for a public offering of 9,756,100 shares of common stock at $4.10 per share, dated February 19, 2026; with expected net proceeds of approximately $37 million, or $42.64 million if over-allotment options are exercised.